Metrics to compare | IMNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.1x | −7.4x | −0.2x | |
PEG Ratio | −0.59 | −0.23 | 0.00 | |
Price/Book | 4.4x | 4.0x | 2.6x | |
Price / LTM Sales | - | 94.7x | 2.8x | |
Upside (Analyst Target) | 80.4% | 57.0% | 65.5% | |
Fair Value Upside | Unlock | 9.2% | 8.9% | Unlock |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.